Edwards Lifesciences Management Performance Evaluation

EW -- USA Stock  

USD 153.60  0.49  0.32%

Analysis of Edwards Lifesciences manpower and management performance can provide insight into Edwards Lifesciences stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with Edwards Lifesciences future performance. Additionally see Investing Opportunities.

Edwards Lifesciences Management Effectiveness

The company has Return on Asset (ROA) of 11.51 % which means that for every $100 of asset it generated profit of $11.51. This is typical in the industry. Likewise, it shows return on total equity (ROE) of 18.7 % which means that it produced $18.7 on every 100 dollars invested by current stockholders.

Edwards Lifesciences Profit Margins

The company has Net Profit Margin (PM) of 16.25 % which may suggest that it has a good control over its expenditures, executes well on its competitive polices, or have a solid pricing strategies. This is very large. Likewise, it shows Net Operating Margin (NOM) of 30.64 % which signify that for every $100 of sales it has a net operating income of 0.31.

Edwards Lifesciences Insider Trading

Edwards Lifesciences Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of seventeen. Edwards Lifesciences Price Series Summation is a cross summation of Edwards Lifesciences price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Edwards Lifesciences Stakeholders

Michael Mussallem Chairman and CEO, Ph.D
Catherine Szyman Corporate Vice President Critical Care, MBA
Huimin Wang Corporate Vice President Japan, Asia Pacific, MBA
Bernard Zovighian Corporate Vice President -Surgical Heart Valve Therapy, MBA
David Erickson Vice President - Investor Relations
Scott Ullem CFO and Corporate VP, MBA
John Cardis Independent Director
Wesley Schack Presiding Independent Director, MBA
Nicholas Valeriani Director, MBA
Leslie Heisz Director, MBA
Martha Marsh Director, MBA
Barbara McNeil Independent Director, Ph.D
Steven Loranger Director
William Link Independent Director
Kieran Gallahue Director, MBA
Larry Wood Corporate VP of Transcatheter Heart Valve, MBA
Patrick Verguet Corporate VP of EMEA, Canada and Latin America, Ph.D
Donald Bobo Corporate VP of Strategy and Corporate Devel.

Leadership

Edwards Lifesciences Top Executives
  Michael Mussallem  Chairman
Chairman and CEO
  Catherine Szyman  President
Corporate Vice President Critical Care

Tenure Analysis

Edwards Lifesciences Employment Tenure
Edwards Lifesciences employes about 12200 people. The company is managed by 18 executives with total tenure of roughly 125 years, averanging almost 6.0 years of service per executive having 677.0 employee per reported executive.

Earnings

Edwards Lifesciences Earnings Estimates
EPSEstimate Date
Quarterly Estimate0.83April 25, 2017
Edwards Lifesciences Corporation normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Manpower Efficiency

Return on Edwards Lifesciences Manpower
Revenue Per Employee 275.3 K
Revenue Per Executive 191.7 M
Net Income Per Employee 53.8 K
Net Income Per Executive 31.1 M
Working Capital Per Employee 128.8 K
Working Capital Per Executive 87.3 M

Per Employee

Edwards Lifesciences Per Employee Growth Over Time

Net Income Per Employee

Revenue Per Employee

Number of Employees

Edwards Lifesciences Number of Employees Analysis
Edwards Lifesciences Corporation is rated below average in number of employees category among related companies. The total workforce of Healthcare Products industry is currently estimated at about 425,400. Edwards Lifesciences holds roughly 12,200 in number of employees claiming about 2.87% of equities under Healthcare Products industry.
Additionally see Investing Opportunities. Please also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.